Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosylhomocysteinase pseudogene 4 (AHCYP4) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a functional gene but is typically non-coding and does not translate into a functional protein. It is not implicated in any known biological function, disease process, or therapeutic pathway. The functional homolog, AHCY, encodes S-adenosylhomocysteine hydrolase, an enzyme implicated in methylation processes and cancer, but AHCYP4 itself has no described role in health or disease[2]. No drugs, biomarkers, molecular mechanisms, or disease associations are documented for this pseudogene. For biomedical research or translational applications, the relevant gene is likely AHCY (S-adenosylhomocysteine hydrolase), not AHCYP4[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosylhomocysteinase pseudogene 4 (AHCYP4).